Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress

On June 18, 2020 Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, reported the company’s participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020 (Press release, Personalis, JUN 18, 2020, View Source [SID1234561234]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Personalis will present "Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform" in an industry-sponsored symposium, featuring the Personalis universal cancer immunogenomics platform, ImmunoID NeXT. Erin Newburn, MS, PhD, will present for Personalis.

Dr. Newburn will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response utilizing analytics including human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, and oncoviral detection, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status. In addition, Dr. Newburn will present a recent case study from a cohort of metastatic melanoma patients who were treated with an immune checkpoint blockade, where we integrated several different molecular features from the ImmunoID NeXT Platform to help better define the responder and non-responder patients.

Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting

On June 18, 2020 Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-focused oncology products in the precision medicine metastatic breast cancer arena, reported that it will share a poster and audio presentation on its lead investigational drug, lasofoxifene, for the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II (Press release, Sermonix Pharmaceuticals, JUN 18, 2020, View Source [SID1234561218]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract compares the efficacy of lasofoxifene, a selective estrogen receptor modulator (SERM), and CDK 4/6 inhibitor palbociclib combinations to that of fulvestrant, a selective estrogen receptor degrader (SERD), and palbociclib combinations in NSG mice with breast tumors carrying Y537S ESR1 mutations.

Presentation Details:
Title: "Lasofoxifene Alone or in Combination With Palbociclib as an Effective Treatment for Therapy-Resistant ER+ Metastatic Breast Cancer"
Session: PO.EN02.01 – Molecular, Preclinical, and Clinical Endocrinology 2
Abstract ID: 4370/ 13
Date + Time: June 22 from 9 a.m. EDT to 6 p.m.

Following the virtual presentation, the poster will be available in the Medical Meetings section of the Sermonix Pharmaceuticals website.

"The results demonstrate a positive, synergistic efficacy of lasofoxifene with a CDK 4/6 inhibitor, supporting this type of combination therapy approach in clinical studies," said David Portman, Sermonix founder and chief executive officer. "We look forward to detailing these new results during this important AACR (Free AACR Whitepaper) online gathering of the oncology community and initiating a Phase 2 combination study in the near future."

The study was conducted by the University of Chicago’s Ben May Department for Cancer Research.

"This work marks an important step in continuing to build the foundation of our ongoing, robust ELAINE clinical development program," said Beth Attias, Sermonix chief strategy and development officer. "We are grateful for the collaboration with the University of Chicago and this groundbreaking work of Dr. Geoffrey Greene."

About Lasofoxifene
Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer.

Amgen To Present At The BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

On June 18, 2020 Amgen (NASDAQ: AMGN) reported that it will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference at 4:00 p.m. ET on Tuesday, June 23, 2020 (Press release, Amgen, JUN 18, 2020, View Source [SID1234561235]). Elliott Levy, senior vice president of R&D Strategy and Operations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen’s website for 90 days following the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


NantHealth Presented Clinical Data on Immunotherapy, Molecularly Targeted Agents and Tumor Biology at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

On June 18, 2020 NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, reported the publication of four abstracts on developmental therapeutics for immunotherapy, molecularly targeted agents and tumor biology during the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 Virtual Scientific Program (Press release, NantHealth, JUN 18, 2020, View Source [SID1234561219]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program, held virtually from May 29-31, 2020, gathered oncology physicians, biotechnology executives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care.

Alongside ImmunityBio, LLC, and others, Dr. Sandeep K. Reddy, Chief Medical Officer at NantHealth, and Christopher Szeto, Director of Machine Learning at NantHealth, presented the data gathered from NantHealth’s database which was used to advance findings in developmental therapeutics.

The details of NantHealth’s ASCO (Free ASCO Whitepaper) posters are as follows:

Title: "Effect of chemokine signaling signatures on resolving discrepancy between TMB and checkpoint expression"
Authors: Saihitha Veerapaneni, Rahul Parulkar, Sandeep K. Reddy, Shahrooz Rabizadeh, Stephen Charles Benz and Christopher Szeto; ImmunityBio, LLC, Culver City, CA; NantHealth, Culver City, CA
Abstract Number: 3131
Session Title: Developmental Therapeutics—Immunotherapy

"In this study, 1,395 clinical samples from the NantHealth database with matched tumor normal whole exomes and deep whole-transcriptomic sequencing were analyzed to confirm previous findings that Tumor Mutation Burden (TMB) and PDL1 mRNA were not correlated," said Dr. Sandeep K. Reddy, Chief Medical Officer, NantHealth. "However, chemokine activity may be an alternative to TMB and PDL1 to identify patients appropriate for immunotherapy and can help resolve discordant cases."

Title: "Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities"
Authors: Jacob J. Adashek, Christopher Szeto, J. Zack Sanborn, Sandeep K. Reddy, Amir A. Toor, Stamatina Danielides, Steven Smith, Steven R. Grossman, Charles V Clevenger, Anthony Faber, Andrea Ferreira-Gonzalez, Sosipatros Alexandros Boikos; University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; NantHealth, Culver City, CA
Abstract Number: 3576
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

"The Cancer Genome Atlas (TCGA) data for 7,087 patients and about 2,700 patients in the NantHealth database were used to identify differential patterns of checkpoint gene expression across different ethnic groups," said Dr. Sandeep K. Reddy, Chief Medical Officer, NantHealth. "White breast cancer patients might be anticipated to exhibit reduced sensitivity to PD1/CTLA4 blockade, while Black colon cancer patients may exhibit reduced sensitivity to IDO1 therapies, such as epacadostat. Ethnicity may represent a significant factor for efficacy checkpoint blockade therapies."

Title: "Highly accurate automated tissue classification using deep learning on digital pathology images: A novel tool for resolving conflicts in diagnosis"
Authors: Liudmila Beziaeva, Mustafa Jaber, Stephen Charles Benz, Shahrooz Rabizadeh, and Christopher Szeto, ImmunityBio, LLC, Culver City, CA; NantHealth, Culver City, CA
Abstract Number: 3578
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

"NantHealth combined whole slide imaging with deep neural networks to develop a tool which can identify which of 24 primary tumor types a sample is derived from with 94.6 percent accuracy," said Christopher Szeto, Director of Machine Learning, NantHealth. "This accuracy, which approaches that of a human pathologist, is achieved by focusing machine-vision attention on just tumor regions within bulk samples. Used in conjunction with molecular profiling, rates of Cancers of Unknown Primary (CUP) or misdiagnosis can feasibly be minimized to improve patient care."

Title: "High correlation between TMB, expressed TMB, and neoantigen load using tumor: Normal whole exome DNA and matched whole transcriptome RNA sequencing"
Authors: Christopher Szeto, Mrinal M. Gounder, Rahul Parulkar, Andrew Nguyen, Shahrooz Rabizadeh, Sandeep K. Reddy; Memorial Sloan Kettering Cancer Center, New York, NY; ImmunityBio, LLC, Culver City, CA; NantHealth, Culver City, CA
Abstract Number: e15238
Session Title: Publication Only: Developmental Therapeutics—Immunotherapy

"Surprisingly, we see minimal difference between the various biomarkers derived from mutational burden," said Christopher Szeto, Director of Machine Learning, NantHealth. "Tissue-specific TMB thresholds may be useful in patient with Sarcoma and Pancreatic cancers. Otherwise, additional data inputs such as microbiome, chemokine expression, and TME cell phenotyping may be required to improve upon TMB as a biomarker of immunotherapy response."

Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

On June 18, 2020 Almac Discovery reported that it will present significant new data on their lead Oncology programmes – the next generation protein drug conjugate programme targeting ROR1 and its lead small molecule inhibitor programme targeting USP7 in poster sessions at this year’s American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II, which is being held June 22-24, 2020 (Press release, Almac, JUN 18, 2020, View Source [SID1234561236]). Both programmes are advancing towards the nomination of candidate drugs, and the new data highlight significant progress that has been made in the last year towards this goal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have developed ADP-c165, a potent and selective ROR1-targeting protein drug conjugate that exploits the properties of small VNAR protein domains. This agent shows excellent efficacy in patient-derived xenograft models with complete and durable regressions observed. We are excited to share this data at the 2020 AACR (Free AACR Whitepaper) Virtual Annual Meeting and the potential of this novel PDC for the treatment of solid tumour indications, particularly triple-negative breast cancer," commented Graham Cotton, Head of Protein Therapeutics, Almac Discovery.

Xavier Jacq, VP Biology at Almac Discovery, said, "Using our potent and highly selective USP7 inhibitors, we have uncovered a completely novel mode of action for USP7 in modulating and reprograming the tumour microenvironment by directly impacting VEGF secretion from fibroblasts. In addition to the established modulation of the p53/MDM2 pathway in cancer cells, this important finding supports new opportunities for combining USP7 inhibitors with immune modulators. We are delighted to share our recent discovery differentiating USP7 inhibition from MDM2 antagonists at the upcoming AACR (Free AACR Whitepaper) Virtual Annual Meeting."

Details are as follows:

Title: Discovery of a novel function for USP7 inhibitors: Reprogramming the tumour microenvironment
Authors: Anamarija Jurisic, Julien Daubriac, Mark Wappett, Ian T. Lobb, Aaron Cranston, Stephanie Burton, Peggy Sung, Gerald Gavory, Colin R. O’Dowd, Tim Harrison, Xavier Jacq. Almac Discovery, Belfast, UK
Abstract Number: 8303
Session: Drug Targets in the Microenvironment
Poster Number: #6057
Type: E-poster
Date & Time: 22 June (9:00 a.m. – 6:00 p.m. EDT)

Title: Exploiting the properties of VNAR domains for the development of novel efficacious protein drug conjugates targeting the oncofetal protein ROR1
Authors: Graham Cotton, Jennifer Thom, Paul Trumper, Andrei Kamenski, Stacey Bell, Mark Wappett, Caroline Barelle, Marina Kovaleva, Alicia Campion, Elisa Persiani, Andrew Porter, Estelle McLean, Aidan McCann, Chiara Saladino, Aaron Cranston, Tim Harrison. Almac Discovery, Edinburgh, United Kingdom, Elasmogen Ltd, Aberdeen, United Kingdom, Almac Discovery, Belfast, UK
Abstract Number:2785
Session: Antibody Technologies
Poster Number: 538
Type: E-poster
Date & Time: 22 June (9:00 a.m. – 6:00 p.m. EDT)